4M Therapeutics Inc. Announces Oversubscribed $2.575 Million Financing Round
FOR IMMEDIATE RELEASE
4M Therapeutics Inc. Announces Oversubscribed $2.575 Million Financing Round
July 20, 2023
Contact:
Ben Williams, Chief Business Officer
Email: info@4mtx.net
Skillman, NJ — 4M Therapeutics Inc. (4MTx), a biotechnology innovator in the field of Central Nervous System (CNS) disorder treatments, has completed a $2.575 million financing round, surpassing the original goal of $1.5 million. The total investment in 4MTx is $4 million to date.
This investment round included the participation of company founders, all members of the Board of Directors, five consultants, and three advisors to the company. Investors in the financing include professionals with vast pharmaceutical experience, including three current biotech CEOs, as well as high net-worth individuals committed to the advancement of treatments for Bipolar and Alzheimer's Disease.
Mark Pavao, Managing Partner of Biotech Value Advisors, explained why he invested in 4MTx: “In my over 30 years of experience in global biopharma commercialization I have helped bring many neuroscience drugs to market, including blockbusters Abilify and Nurtec-ODT. 4MTx’s lead program targets meaningful improvement to the current standard of care in a large psychiatric indication that has significant unmet need. Once approved, I am confident that 4MTx can successfully scale and execute its commercial launch plan.”
Pablo Lapuerta, MD, Chief Executive Officer of 4MTx, stated, "We are grateful to all the investors who have placed their trust in 4MTx. Together we are committed to developing new treatments that improve the lives of those battling Bipolar Disorder, Alzheimer's Disease, and the other CNS disorders where we can have a positive impact."
About 4MTx:
4M Therapeutics Inc. (4MTx) is a biotechnology startup dedicated to the development of new treatments for CNS disorders, utilizing living human brain cells to transform drug discovery. Concentrating on conditions like bipolar disorder, Parkinson's, and Alzheimer's, where neural plasticity is impaired, the 4MTx pipeline includes two GSK3B inhibitors, a glutamate antagonist, and a CDK5 inhibitory peptide. With a lead program slated for human clinical trials in 2025, and world-renowned scientific founders in neurobiology, chemistry, and regenerative medicine, 4MTx is positioned at the forefront of neuroscience. To learn more or to engage with us, visit www.4mtx.net or follow us on LinkedIn.
